Type 2 diabetes. Type 2 diabetes mellitus with other specified complications
Conditions
Interventions
Intervention 1: Intervention group: Receive a low-calorie MIND diet for 3 months. The required energy will be calculated based on the World Health Organization equations and 500 kcal will be deducted
Sponsors
Kermanshah University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
30 Years to 65 Years
Inclusion criteria
Inclusion criteria: Women with type 2 diabetes Desire to participate in the study Age range from 30 to 65 years old Body mass index between 25 and 35 kg/m2 Suffering from insomnia disorder, based on the Insomnia Severity Index (ISI) questionnaire, with scores above 7
Exclusion criteria
Exclusion criteria: Insulin use Pregnancy and lactation Alcohol and smoking Sleep apnea Shift work Special diets and medications for weight loss in the last 3 months Suffering from other endocrine, metabolic, kidney and neurological diseases Taking medications (sedatives, painkillers, sleeping pills, etc.) other than blood sugar, lipid, and blood pressure lowering medications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sleep quality. Timepoint: Baseline and End-of-trial. Method of measurement: The Pittsburgh Sleep Quality Index. | — |
Secondary
| Measure | Time frame |
|---|---|
| Depression-anxiety-stress. Timepoint: Baseline and End-of-trial. Method of measurement: Depression Anxiety and Stress Scale-21 questionnaire.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic method.;HbA1C. Timepoint: Baseline and End-of-trial. Method of measurement: Photometric method.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Triglyceride. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic method.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic method.;HDL Cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic method.;Brain-derived neurotrophic factor. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Cortisol. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Total Antioxidant Capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Calorimetric method.;Total oxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Calorimetric method.;GSH-Px. Timepoint: Baseline and End-of-trial. Method of measurement: Calorimetric method.;Catalase. Timepoint: Baseline and End-of-trial. Method of measurement: Calorimetric method.;SOD. Timepoint: Baseline and End-of-trial. Method of measurement: Calorimetric method.;MDA. Timepoint: Baseline and End-of-trial. Method of measurement: Calorimetric method.;Quality of life. Timepoint: Baseline and End-of-trial. Method of measurement: 36-Item Short Form Survey.;LDL Cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Friedewald.;Blood pressure. Timepoint: Baseline and End-of-trial. Method of measurement: Sphygmomanometer.;Weight. Timepoint: Baseline and End-of-trial. Method of measurement: Digital scale.;Body mass index. Timepoint: Baseline and End-of-trial. Method of measurement: Dividing weight (in kilog | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Mostafa Nachvak
Kermanshah University of Medical Sciences
Outcome results
None listed